Benralizumab (3) – Fasenra®
Hypereosinophilic syndrome, aged ≥ 12 years, weighing ≥ 35 kg
Characteristics
| Start date | 15.07.2026 |
|---|---|
| Resolution | 07.01.2027 – active procedure |
| INN | Benralizumab |
| Brand name | Fasenra® |
| Pharm. company | AstraZeneca GmbH |
| G-BA Procedure ID | D-1357 |
| Therapeutic area | Hematopoietic diseases |
| Reason for procedure | New therapeutic indication |
Associated procedures
| Benralizumab (3) | Fasenra® | AstraZeneca GmbH | Hypereosinophilic syndrome, aged ≥ 12 years, weighing ≥ 35 kg | n.d. | active procedure | |
| Benralizumab (2) | Fasenra® | AstraZeneca GmbH | Eosinophilic granulomatosis with polyangiitis | 90–1,360 | 100% additional benefit not proven | |
| Benralizumab (1) | Fasenra® | AstraZeneca GmbH | Bronchial asthma | 6,800–80,000 | 50% Hint for minor additional benefit |
<< List of all resolutions